Curaleaf (OTCMKTS:CURLF - Get Free Report) was upgraded by research analysts at Canaccord Genuity Group to a "strong-buy" rating in a research note issued to investors on Thursday,Zacks.com reports.
Separately, Cormark raised Curaleaf from a "hold" rating to a "moderate buy" rating in a research report on Friday, August 8th. Two analysts have rated the stock with a Strong Buy rating, According to MarketBeat, the stock presently has a consensus rating of "Strong Buy".
Read Our Latest Report on CURLF
Curaleaf Price Performance
CURLF opened at $3.31 on Thursday. The stock has a market cap of $2.22 billion, a price-to-earnings ratio of -10.36 and a beta of 0.71. Curaleaf has a 1 year low of $0.68 and a 1 year high of $3.65. The company has a current ratio of 1.47, a quick ratio of 0.70 and a debt-to-equity ratio of 1.00. The stock has a fifty day moving average price of $2.72 and a 200 day moving average price of $1.54.
Curaleaf (OTCMKTS:CURLF - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.07) by $0.01. Curaleaf had a negative return on equity of 14.61% and a negative net margin of 18.08%. Analysts forecast that Curaleaf will post -0.25 EPS for the current fiscal year.
Curaleaf Company Profile
(
Get Free Report)
Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Curaleaf, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Curaleaf wasn't on the list.
While Curaleaf currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.